Evidence map›Paper›PMID 37203465›Full record

ArticleCancer science2023

Novel positron emission tomography imaging targeting cell surface glycans for pancreatic cancer:

Yukihito Kuroda, Tatsuya Oda, Osamu Shimomura, Pakavarin Louphrasitthiphol, Bryan J Mathis, Hiroaki Tateno, Kentaro Hatano

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Yukihito KurodaDepartment of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.ORCID https://orcid.org/0000-0002-6920-6731
Tatsuya OdaDepartment of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.ORCID https://orcid.org/0000-0001-6115-0158
Osamu ShimomuraDepartment of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
Pakavarin LouphrasitthipholDepartment of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
Bryan J MathisInternational Medical Center, University of Tsukuba Hospital, Tsukuba, Japan.
Hiroaki TatenoCellular and Molecular Biotechnology Research Institute, National Institute of Advanced Industrial Science and Technology, Tsukuba, Japan.
Kentaro HatanoDepartment of Applied Molecular Imaging, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.ORCID https://orcid.org/0000-0001-8154-3119
University of Tsukuba · JPNational Institute of Advanced Industrial Science and Technology · JPUniversity of Tsukuba Hospital · JP

Funding

JSPS KAKENHI JP19H05557JSPS KAKENHI JP20KA20467
6 · The paper itself

Abstract

Advancement in early detection modalities will greatly improve the overall prognoses of pancreatic ductal adenocarcinoma (PDAC). For this purpose, we report a novel class of tumor-specific probes for positron emission tomography (PET) based on targeting cell surface glycans. The PDAC-targeting ability of rBC2LCN lectin, combined with fluorine-18 (

Indexed as

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsAnimalsCell Line, TumorFluorine RadioisotopesHumansLectinsMiceMice, NudePositron-Emission TomographyRadiopharmaceuticalsFluorine-18Fluorine RadioisotopesLectinsRadiopharmaceuticalsrBC2LCN lectinfluorine-18lectinmolecular imagingpancreatic cancerPET

Identifiers

PMID37203465
PMCPMC10394132
OpenAlexW4377092983

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.